Comparison of the 48-week efficacy between entecavir and adefovir in HBeAg-positive nucleos(t)ide-nave Asian patients with chronic hepatitis B: A meta-analysis

Virology Journal

Volumn 8, Issue , 2011, Pages

  Zhao, Pan ^a   Liu, Weiwei ^b   Zhao, Jun ^a   Guan, Qun ^a  

^a BEIJING 302 HOSPITAL   (China)

^b BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; ENTECAVIR; HEPATITIS B(E) ANTIGEN; VIRUS DNA; ADENINE; ANTIVIRUS AGENT; DRUG DERIVATIVE; GUANINE; PHOSPHONIC ACID DERIVATIVE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; DRUG EFFICACY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; META ANALYSIS; SEROCONVERSION; TREATMENT DURATION; ASIA; BLOOD; COMPARATIVE STUDY; IMMUNOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW;

HEPATITIS B VIRUS;

ADENINE; ANTIVIRAL AGENTS; ASIA; GUANINE; HEPATITIS B E ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; PHOSPHONIC ACIDS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 79951789406     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-8-75     Document Type: Article

References (23)

1. Clinical relevance and public health significance of hepatitis B virus genomic variations. GW Cao, World J Gastroenterol 2009 15 46 5761 5769 10.3748/wjg.15.5761 19998495
2. Does RNA interference provide new hope for control of chronic hepatitis B infection? R Wilson D Purcell HJ Netter PA Revill, Antivir Ther 2009 14 7 879 889 10.3851/IMP1424 19918092
3. Hepatitis B virus resistance to nucleos(t)ide analogues. F Zoulim S Locarnini, Gastroenterology 2009 137 1593 1608 10.1053/j.gastro.2009.08.063 19737565
4. The oncogenic potential of hepatitis B virus rtA181T/surface truncation mutant. MW Lai CT Yeh, Antivir Ther 2008 13 875 879 19043921
5. Antiviral resistance and hepatitis B therapy. MG Ghany EC Doo, Hepatology 2009 49 5 174 s184 10.1002/hep.22900 19399794
6. Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses. G Woo G Tomlinson Y Nishikawa M Kowgier M Sherman DK Wong B Pham WJ Ungar TR Einarson EJ Heathcote M Krahn, Gastroenterology 2010 139 1218 1229 10.1053/j.gastro.2010. 06.042 20600036
7. Benefits and risks of nucleoside analog therapy for hepatitis B. JL Dienstag, Hepatology 2009 49 112 S121 10.1002/hep.22920 19399795
8. Comparison between the anti-HBV effects of entecavir and adefovir. H Ding, Shi Jie Gan Ran Za Zhi (World Infect J) 2007 7 4 303 304
9. Efficacy of entecavir in nucleos(t)ide-naive patients with hepatitis B e antigen-positive chronic hepatitis B. Q Zhang ML Cheng Q Liu M Mu YY Zhang BY Liu, Shi Jie Hua Ren Xiao Hua Za Zhi (World Chin J Digestol) 2009 17 27 2846 2849
10. Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: a randomized international study of entecavir versus adefovir. N Leung CY Peng HW Hann J Sollano J Lao-Tan CW Hsu L Lesmana MF Yuen L Jeffers M Sherman A Min K Mencarini U Diva A Cross R Wilber J Lopez-Talavera, Hepatology 2009 49 1 72 79 10.1002/hep.22658 19065670
11. Comparison of efficacy between adefovir dipivoxil and entecavir in patients with chronic hepatitis B. F Yang XF Wei Ni Wei, Zhong Hua Gan Zang Bing Za Zhi (Chin J Hepatol) 2010 18 1 65 66
12. Comparision of the efficacy of two kinds of antiviral drugs: adefovir and entecavir. S Zou XS Li XJ Li, Zhong Guo Xian Dai Yi Xue Za Zhi (Chin J Modern Med) 2010 20 9 1391 1393
13. Random study of entecavir and adefovir dipivoxil in patients with chronic hepatitis B. H Huang XH Xu T Ma YF Gao J Cheng Y Ye ZS Zhou QX Xie SF Wei F Su JB Li, Zhong Guo Xian Dai Yi Xue Za Zhi (Chin J Practical Intern Med) 2010 30 6 548 549
14. Side effects of long-term oral antiviral therapy for hepatitis B. RJ Fontana, Hepatology 2009 49 185 S195 10.1002/hep.22885 19399802
15. Therapeutic strategies in the management of patients with chronic hepatitis B virus infection. GV Papatheodoridis S Manolakopoulos G Dusheiko AJ Archimandritis, Lancet Infect Dis 2008 8 167 178 10.1016/S1473-3099(07)70264-5 18053766 (Pubitemid 351249242)
16. Novel mutation in YMDD motif and direct neighbourhood in a child with chronic HBV-infection and clinical lamivudine and adefovir resistance - a scholarly case. V Schildgen S Ziegler RL Tillmann O Schildgen, Virol J 2010 21 7 167 10.1186/1743-422X-7-167
17. HBV DNA level as an important determinant of E antigen seroconversion of chronic hepatitis B during adefovir dipivoxil therapy. KC Tseng PN Cheng IC Wu CK Chang AL Chou WC Liu TT Chang, Hepatogastroenterology 2009 56 91-92 813 818 19621708
18. Resistance to adefovir: a new challenge in the treatment of chronic hepatitis B. P Maecellin T Asselah, J Hepatol 2005 43 920 923 16246449 (Pubitemid 41627973)
19. Efficacy and durability of generic adefovir dipivoxil in patients with HBeAg positive chronic hepatitis. PL Dong DM Wang XM Zhang B Zhang HG Ding J Min XY Chen, Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi (Chin J Exp Clin Virol) 2009 23 6 473 475
20. Antiviral therapy of chronic hepatitis B. F Zoulim, Antivir Res 2006 71 206 215 10.1016/j.antiviral.2006.04.003 16716414 (Pubitemid 44223759)
21. Efficacy and safety of entecavir compared to lamivudine in nucleoside-nave patients with chronic hepatitis B: a randomized double-blind trail in China. G Yao C Chen W Lu H Ren D Tan Y Wang D Xu Z Jiang J Liu D Xu L Macdonald and for the AI463023 Study Group, Hepatol Int 2007 1 365 372 10.1007/s12072-007-9009-2 19669331
22. Endpoints of therapy in chronic hepatitis B. JJ Feld DKH Wong EJ Heathcote, Hepatology 2009 49 96 s102 10.1002/hep.22977 19399800
23. Efficacy of adefovir add-on lamivudine rescue therapy compared with switching to entecavir monotherapy in patients with lamivudine-resistant chronic hepatitis B. HJ Ryu JM Lee SH Ahn Y Kim do MH Lee KH Han CY Chon JY Park, J Med Virol 2010 82 1835 1842 10.1002/jmv.21898 20872709